Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. These activites are not approved for AMA PRA Category 1 Credit™
This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
720 S. Michigan Avenue
International Ballroom North (Lobby Level)
Chicago, IL 60605
Phone: (312) 922-4400
Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient Outcomes is a live symposium to be held adjunct to the annual meeting in Chicago. The management of advanced forms of lung cancer has been transformed in recent years because of remarkable developments in molecular diagnostics and new therapies. The targeting of known oncogenic drivers has allowed for the development of strategies that aim to improve efficacy and minimize toxicity compared with previous standards of care. Indeed, personalized care is now the standard of care in non–small cell lung cancer (NSCLC). Tyrosine kinase inhibitors (TKIs) have brought hope to patients with several types of cancer in multiple lines of therapy, including epidermal growth factor receptor (EGFR)-mutated and anaplastic lymphoma kinase (ALK)-translocated NSCLC. In patient populations that have received targeted treatments, impressive clinical benefit has been achieved with TKIs that target mutated EGFR or ALK. These changes are welcome, and the field continues to move forward, with new diagnostic techniques and an ever-expanding array of therapeutic options in the different lines of therapy. The continual advances in the treatment of patients with oncogenic driver–mutated NSCLC create practice and educational gaps for clinical oncologists who strive to maintain state-of-the-art care for their patients. To meet this educational need, this interactive live symposium has assembled internationally recognized experts in lung cancer research and care to provide cutting-edge approaches that can be applied immediately to clinical practice.
Key topics to be addressed include:
The symposium will be held at the Hilton Chicago, on June 4, 2017, from 7:00 PM-9:00 PM. Please join us in Chicago for expert advice on oncogene-targeted therapy in lung cancer. This is a program you won’t want to miss!
This educational activity is directed toward medical oncologists who treat patients with lung cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of cancer will be invited to participate.
David R. Gandara, MD
Professor of Medicine
Division of Hematology/Oncology
Director, Thoracic Oncology Program
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
ASH: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients with GvHD
December 8, 2017
ASH: Evaluating the Emerging Role of Biosimilar Agents for the Treatment of Hematologic Malignancies
December 8, 2017
Addressing Challenges and Personalizing Care in Postsurgical Pain Management - Brunch With the Experts
Dec 29, 2017